Multiple myeloma trials in China

In China 203 Also abroad 703

203 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients
Where
Dongyang, Hangzhou, Huzhou, Jiaxing, Jinhua, Lishui, Ningbo, Shaoxing, Taizhou, Wenzhou
Age
18 years to 75 years
People
99
Run by
The Affiliated People's Hospital of Ningbo University
See details and how to joinNCT06520176
No phaseTaking people
Safety and Efficacy of Anti-BCMA-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM
Where
Kunming
Age
18 years to 75 years
People
10
Run by
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
See details and how to joinNCT06515262
Phase 1Not yet taking people in China
A Study of QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma
Where
Tianjin
Age
18 years and over
People
90
Run by
Qilu Pharmaceutical Co., Ltd.
See details and how to joinNCT06500507
No phaseNot yet taking people in China
LCAR-M61S and LCAR-M61D in Treatment of Relapsed/Refractory Multiple Myeloma
Where
Beijing, Hefei, Nanjing, Zhengzhou
Age
18 years and over
People
66
Run by
The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT06472479
No phaseTaking people
Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not
Where
Hangzhou
Age
18 years to 70 years
People
210
Run by
First Affiliated Hospital of Zhejiang University
See details and how to joinNCT06463717
Early phase 1Taking people
Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma
Where
Shanghai
Age
18 years and over
People
10
Run by
Shanghai Changzheng Hospital
See details and how to joinNCT06407947
Phase 1/2Taking people
OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM
Where
Beijing, Hangzhou, Nanjing, Shanghai, Wuhan
Age
18 years to 75 years
People
83
Run by
OriCell Therapeutics Co., Ltd.
See details and how to joinNCT06182696
No phaseNot yet taking people in China
A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma.
Where
Beijing
Age
18 years and over
People
260
Run by
Peking University People's Hospital
See details and how to joinNCT06369935
Phase 1/2Taking people
A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.
Where
Beijing
Age
18 years and over
People
154
Run by
Beijing Mabworks Biotech Co., Ltd.
See details and how to joinNCT06232096
Early phase 1Not yet taking people in China
To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma
Where
Guangzhou
Age
18 years to 75 years
People
15
Run by
Guangdong Second Provincial General Hospital
See details and how to joinNCT06298266
No phaseTaking people
UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma
Where
Suzhou
Age
18 years and over
People
15
Run by
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
See details and how to joinNCT06279026
Phase 1/2Taking people
Mitoxantrone Hydrochloride Liposome Combination Regimen in the Treatment of High-risk/Extramedullary Multiple Myeloma
Where
Nantong
Age
18 years to 70 years
People
30
Run by
Affiliated Hospital of Nantong University
See details and how to joinNCT06246162
Phase 1/2Taking people
Safety and Efficacy of Anti-FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)
Where
Xuzhou
Age
18 years to 70 years
People
20
Run by
Xuzhou Medical University
See details and how to joinNCT06196255
Phase 2Taking people
DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma
Where
Tianjin
Age
18 years to 70 years
People
40
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT06158269
No phaseTaking people
Cardiac Toxicity and Prognostic Value of New Echocardiographic Indicators in the Treatment of Primary Multiple Myeloma
Where
Jinan
Age
18 years to 70 years
People
50
Run by
Qilu Hospital of Shandong University
See details and how to joinNCT06039735
Phase 1/2Taking people
Safety and Efficacy of APRIL-BAFF-Bicephali CAR-T in Relapsed, Refractory Multiple Myeloma
Where
Xuzhou
Age
18 years to 70 years
People
20
Run by
Xuzhou Medical University
See details and how to joinNCT06132711
Early phase 1Taking people
To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL
Where
Shanghai
Age
18 years and over
People
18
Run by
Hrain Biotechnology Co., Ltd.
See details and how to joinNCT06045091
No phaseTaking people
The China M-protein Screening Project in First-degree Relatives of Myeloma Patient - The CHAPERONE Study
Where
Shanghai
Age
18 years and over
People
10,000
Run by
Shanghai Zhongshan Hospital
See details and how to joinNCT05965115
No phaseTaking people
Helical Tomotherapy in Multiple Myeloma
Where
Wuhan
Age
18 years to 75 years
People
58
Run by
Fuling Zhou
See details and how to joinNCT05970198
Phase 1/2Taking people
A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma
Where
Tianjin
Age
18 years and over
People
92
Run by
Shanghai AbelZeta Ltd.
See details and how to joinNCT05521802
Phase 2Taking people
Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM
Where
Shanghai, Wenzhou
Age
18 years to 75 years
People
100
Run by
Hrain Biotechnology Co., Ltd.
See details and how to joinNCT05594797
Early phase 1Taking people
APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma
Where
Hangzhou
Age
18 years to 75 years
People
36
Run by
Zhejiang University
See details and how to joinNCT04657861
Phase 1Not yet taking people in China
A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2)
Where
Changzhou, Hefei, Nanjing
Age
18 years to 70 years
People
20
Run by
Nanjing IASO Biotechnology Co., Ltd.
See details and how to joinNCT05181501
Early phase 1Taking people
CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases
Where
Hangzhou
People
108
Run by
Zhejiang University
See details and how to joinNCT04662294
Early phase 1Not yet taking people in China
A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma
Where
Hangzhou
Age
30 years to 75 years
People
50
Run by
Zhejiang University
See details and how to joinNCT04670055